Semaglutide and GLP-1 in India: What to Know After the 2026 Patent Expiry

On March 20, 2026, Novo Nordisk's Indian semaglutide patent expired and 40+ generic manufacturers launched at 70 to 90% lower prices. India has 100 million diabetics and 250 million people in obese/overweight category under Asian BMI cutoffs. DCGI has cracked down on unsupervised use. Side effects a

Share
GLP-1 injection pen (semaglutide) alongside DCGI regulatory document and India map, semaglutide India context

Important: GLP-1 drugs including semaglutide are prescription-only medications in India under the Drugs and Cosmetics Act. They can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists, and cannot be legally dispensed without a valid prescription from a registered medical practitioner. Do not self-prescribe, purchase online without a valid prescription, or use these drugs without specialist supervision. This article is for informational purposes only and does not constitute medical advice.

On March 20, 2026, Novo Nordisk's core Indian patent on semaglutide expired. Semaglutide is the GLP-1 receptor agonist molecule originally developed and patented by Novo Nordisk for the treatment of Type 2 diabetes and obesity; this article refers to the molecule by its generic name throughout. Within 24 hours, more than 40 Indian pharmaceutical companies had launched generic versions at prices 70% to 90% below what the originator-branded semaglutide had cost. A treatment that had cost Rs. 8,800 to Rs. 11,175 per month is now available at Rs. 1,290 per month in vial format. The price collapse arrived in a country with approximately 100 million people living with diabetes, 136 million pre-diabetic, and an estimated 200 to 230 million adults classified as overweight or obese under India's Asian BMI thresholds, based on NFHS-5 (2019-21) data showing approximately 22 to 24% of Indian adults with BMI at or above 25 kg/m².

The timing is significant. India's drug regulator, the Drug Controller General of India (DCGI), issued a comprehensive advisory on March 10, 2026 to all GLP-1 drug manufacturers to stop misleading advertisements and any promotion that could encourage unsupervised use. In recent weeks, 49 businesses were audited and inspected across the country, including online pharmacy warehouses, drug wholesalers, retailers, and weight loss clinics. Businesses found breaking the rules face licence cancellation, fines, and legal action, according to the PIB Research Document on GLP-1 drugs published April 1, 2026.

Semaglutide's Indian patent expiry is a genuine public health inflection point. But the 90% price drop does not automatically translate to safe or appropriate use. The drug requires specialist supervision, carries serious side effects, treats a chronic disease demanding long-term management, and must be calibrated to India's metabolic profile rather than BMI thresholds designed for Western populations. This guide covers what you need to know before the conversation with your doctor.

SwasthiQ is building Healthcare Rails for India, the connected ecosystem that links a patient's prescriptions, metabolic markers, and specialist visits so a GLP-1 therapy decision is informed by full clinical context rather than made in a wellness clinic operating outside its scope.

Official sources: PIB Research Document, April 1 2026 | Pearce IP, March 21 2026 (generic launch) | STAT News, March 17 2026 (BMI and thin-fat)


What GLP-1 Receptor Agonists Actually Are

GLP-1 (glucagon-like peptide-1, a hormone produced in the gut after eating that signals the pancreas to release insulin and suppresses excess glucagon) is one of the body's primary mechanisms for blood sugar regulation after meals. When food is consumed, GLP-1 is released, triggering insulin production, slowing gastric emptying (the rate at which food moves from the stomach to the small intestine), and reducing appetite. In people with Type 2 diabetes, this hormonal signalling is impaired. Blood sugar rises higher, stays elevated longer, and the body's compensatory mechanisms become progressively less effective.

GLP-1 receptor agonists are drugs that mimic the action of the GLP-1 hormone. They bind to the same receptor and trigger the same effects, but stay active in the bloodstream for much longer than the natural hormone. They were first developed to address this dysfunction in Type 2 diabetes. The first GLP-1 medication was approved by the US FDA in 2005. Researchers subsequently found that the gastric-slowing and appetite-suppressing effects also produced clinically significant weight loss, which led to the drugs' expansion into obesity treatment.

Semaglutide, the originator molecule developed by Novo Nordisk and approved for both Type 2 diabetes and obesity, is administered once weekly as a subcutaneous injection (an injection delivered just beneath the skin, not into a vein or muscle). An oral form of semaglutide is also available but requires strict administration conditions (empty stomach, specific water intake, 30 minutes before food) and has less consistent absorption. Tirzepatide, the dual agonist molecule manufactured by Eli Lilly, targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide, another gut hormone involved in insulin release and fat storage) receptors, producing even greater weight loss in trial data.


The Clinical Evidence: What the Trials Actually Show

The evidence base for semaglutide is among the most substantial in recent pharmacology. The STEP-1 trial found that weekly semaglutide injection produced an average weight loss of approximately 15% over 68 weeks in people with obesity. The SELECT trial, the cardiovascular outcomes study, found that semaglutide reduced major cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in people with obesity and established cardiovascular disease, establishing the drug's credentials beyond metabolic management alone.

However, two clinical realities are frequently omitted from the popular discourse on these drugs. First, the STEP-1 extension data are unambiguous. Patients who stopped semaglutide at week 68 regained approximately two-thirds of their lost weight within one year. Obesity is a chronic disease, and GLP-1 drugs address it as a chronic disease requires: ongoing treatment, not a finite course. The popular framing of these drugs as a weight-loss treatment obscures their true clinical character as long-term medication for a long-term condition.

Second, the SELECT trial enrolled participants who were 84% white and only 8% Asian. The eligibility threshold of BMI 27 or above was set based on populations where metabolic risk accumulates at higher BMIs. South Asian populations, including Indians, carry substantially greater cardiovascular and metabolic risk at lower body weights. This is not a minor academic distinction. It has direct implications for who in India should be considered for GLP-1 therapy, at what BMI thresholds, and under what prescribing framework.


India's Thin-Fat Problem: Why Western BMI Thresholds Do Not Apply

One of the most important and underreported dimensions of the GLP-1 story in India is the mismatch between how these drugs were studied and how Indian bodies actually work. An ICMR-INDIAB nationally representative analysis (Anjana et al., Lancet Diabetes & Endocrinology 2023) found that 43% of Indian adults are metabolically obese despite having a BMI below 25, a pattern sometimes described as the "thin-fat phenotype" or "metabolically obese normal weight."

The PIB Research Document confirms that India uses Asian BMI cutoffs. Obesity is defined as BMI at or above 25 kg/m², and overweight as BMI between 23.00 and 24.99 kg/m². These are already lower than the global standards of 30 (obesity) and 25 (overweight). The World Health Organisation recognised over two decades ago that cardiovascular and metabolic risk in Asian populations begins accumulating at BMI 23, not at the higher thresholds established for primarily Western populations.

This creates a specific clinical challenge for Indian GLP-1 use. A person with a BMI of 24 who would be classified as normal weight under Western criteria may have significant visceral fat, insulin resistance, and cardiovascular risk. Under Indian cutoffs they are classified as overweight. Under the SELECT trial's US FDA-derived prescribing threshold of BMI 27, they would not qualify for semaglutide for cardiovascular risk reduction at all. A preliminary meta-analysis cited in the STAT News analysis found that GLP-1 drugs reduced cardiovascular events nearly twice as effectively in Asian patients as in white patients, precisely the population most at risk at lower BMIs.

The practical implications for India are significant. The prescribing framework appropriate for India is not a copy of the US framework. CDSCO has received a committee recommendation to study semaglutide's cardiovascular benefit specifically in Indian patients, but that data is not yet available. In the interim, prescribing decisions must be made by qualified specialists who understand the Indian metabolic context, which is precisely why the regulatory requirement for endocrinologist or internal medicine specialist oversight is not bureaucratic caution but a clinical necessity.


India's Regulatory Framework: Who Can Prescribe, Who Cannot

The PIB Research Document is unambiguous on this point. In India, GLP-1 drugs can be prescribed only by endocrinologists, internal medicine specialists, and cardiologists. They cannot be prescribed by general practitioners, dermatologists, wellness doctors, or any other category of physician. They cannot be purchased over the counter. They are prescription-only drugs under the Drugs and Cosmetics Act, meaning a pharmacy cannot legally dispense them without a valid prescription from a registered medical practitioner.

The reason for this specialist restriction is clinical, not administrative. GLP-1 drugs require a proper metabolic evaluation before initiation: assessment of the patient's specific indication (diabetes, obesity, or both), cardiovascular risk profile, kidney function, thyroid history, pancreatic history, and concurrent medications. The dosing protocol requires careful titration over several weeks to minimise gastrointestinal side effects. Follow-up monitoring is required throughout treatment. None of this is appropriate for an unsupervised consultation or a wellness clinic operating outside its clinical scope.

The DCGI's enforcement actions in early 2026 directly reflect the gap between what the regulations require and what was happening in practice. Weight loss clinics, online platforms, wellness programmes, and social media marketing had effectively made GLP-1 drugs available without the clinical evaluation the drugs require. The 49 business inspections and the March 10 advertising advisory represent the regulator's response to a market that moved faster than the oversight structure.


What Is Now Available in India: Brands and Prices

The April 2026 Indian semaglutide market is unlike anything that existed six months ago. The following reflects the landscape as of April 2026, when this blog was written, and prices will continue to evolve.

Originator (Novo Nordisk): Semaglutide for Type 2 diabetes is priced at approximately Rs. 1,415 per weekly injection in India after the April 1, 2026 price reduction (up to 36% off pre-competition pricing). Semaglutide for obesity has been reduced by up to 48%.

Indian generic semaglutide (launched March 21, 2026, after patent expiry):

ManufacturerFormatApprox. monthly cost
Natco PharmaVialRs. 1,290 to 1,750
Alkem LaboratoriesPre-filled penRs. 1,800
Zydus LifesciencesReusable penRs. 2,200
Dr. Reddy's LaboratoriesPre-filled penRs. 4,200
Sun PharmaPre-filled penRs. 3,000 to 5,200
Glenmark PharmaceuticalsVial and penRs. 1,300 to 1,800

All of these contain the identical semaglutide molecule. According to DermaVue's clinical analysis (April 2026), several early DCGI approvals, including Alkem Laboratories, were processed under the Subsequent New Drug pathway, which requires completed Phase III clinical trials in Indian patients, a higher evidentiary standard than the US FDA's bioequivalence-only pathway (which only requires the generic to absorb the same way as the branded drug, without fresh patient trials). Approval pathways may vary across all 40+ manufacturers, and the specific pathway for each brand is the manufacturer's regulatory filing matter. The clinical differences between brands are in delivery device (vial requires syringe drawing vs pre-filled pen), manufacturer, and price.

Tirzepatide (the dual GLP-1/GIP molecule manufactured by Eli Lilly) is separately available in India and, according to trade data cited by Pharmarack Vice President Sheetal Sapale in The Indian Practitioner (March 2026), commands approximately 85% of India's GLP-1 market by value ahead of generic semaglutide entry. Tirzepatide is more expensive than generic semaglutide and produces greater average weight loss (15 to 22% across dose groups in the SURMOUNT-1 trial vs semaglutide's approximately 15%) through its dual GLP-1/GIP mechanism.


Side Effects and Risks: What the PIB Document Confirms

The PIB Research Document states clearly that GLP-1 drugs carry a wide range of side effects, from common symptoms to severe complications. The document explicitly lists pancreatitis, kidney injury, and bowel obstruction as serious risks, alongside nausea and dizziness as common effects. The document also specifically names medullary thyroid cancer as a risk associated with this drug class.

The common side effects in clinical practice are predominantly gastrointestinal: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly in the first two to four weeks of use. These typically improve as the body adjusts and are managed through a slow dose-titration protocol starting at the lowest dose. They are the primary reason that abrupt self-initiation at higher doses, which has been observed in the Indian grey market, is particularly dangerous.

The serious but rarer risks include pancreatitis (inflammation of the pancreas, which can be life-threatening), acute kidney injury (often secondary to dehydration from vomiting and diarrhoea), and bowel obstruction. The medullary thyroid cancer risk observed in animal studies led to a contraindication in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Gallbladder problems, including gallstones and cholecystitis, are also associated with rapid weight loss induced by GLP-1 drugs.

People with kidney disease, active inflammatory bowel disease, a history of pancreatitis, or those taking certain medications that interact with GLP-1 drugs require specific evaluation before use. This is another reason why the specialist-only prescribing requirement is not procedural formality.


Who Should Consider Discussing GLP-1 Drugs With Their Doctor

The following is not a recommendation to take these drugs. It is a guide to who should have a clinical conversation with a qualified specialist.

GLP-1 drugs have established clinical indications in India for two conditions: Type 2 diabetes where blood sugar is not adequately controlled on existing medications, and obesity where lifestyle intervention has been insufficient and co-existing metabolic or cardiovascular risk is present. The prescribing decision requires assessment of multiple factors that a qualified specialist must evaluate, including the specific indication, metabolic baseline, kidney function, thyroid and pancreatic history, and the realistic long-term commitment the treatment requires.

People who should specifically not use these drugs without thorough specialist evaluation include pregnant or breastfeeding women, people with a personal or family history of medullary thyroid carcinoma, people with a history of pancreatitis, people with severe kidney disease, and people with active inflammatory bowel disease.

The single most important decision-support fact for Indian adults considering GLP-1 drugs is this. These are not weight-loss injections for people who want to lose 5 kilograms before a wedding. They are chronic disease medications for clinically defined obesity and diabetes, and their benefits are contingent on continuing them indefinitely. Stopping the medication reverses most of its effects within a year. The treatment is lifelong if it is going to remain effective.


The Access and Equity Dimension

Generic semaglutide at Rs. 1,290 per month is dramatically more accessible than Rs. 11,175 per month. But it is not free, it is not covered by health insurance in India (semaglutide is not on the National List of Essential Medicines, and Indian insurance generally does not cover lifestyle drugs or obesity treatment), and it still requires a specialist consultation that is itself a barrier outside major urban centres.

For a rural Indian patient or a semi-urban patient without easy access to an endocrinologist, the logistical pathway to appropriate GLP-1 therapy involves multiple visits, specialist availability, and consistent monthly expenditure that represents a meaningful share of income. The regulatory framework that requires specialist oversight is necessary for safety but also, practically, limits access.

CDSCO's refusal to follow the US FDA's BMI-27 threshold for cardiovascular indications is the correct clinical position for India. But until India-specific data from semaglutide trials in Indian patients is available, prescribing guidance will remain partly extrapolated from populations where the risk profile differs.


The Bottom Line

India has one of the world's largest diabetes and obesity burdens. Semaglutide, now available at a fraction of its original cost through generic competition, has genuine potential to reduce that burden at scale. The SELECT trial evidence on cardiovascular risk reduction, the preliminary data suggesting GLP-1s may be even more effective in Asian patients, and India's higher metabolic risk at lower BMIs all point to a drug class that could be particularly important for the Indian population.

The barriers to appropriate use are equally real. These drugs require specialist oversight, carry serious side effects, treat chronic conditions requiring indefinite management, and are priced and accessed through pathways that exclude many of the Indians who most need them. The DCGI's March 2026 crackdown on unsupervised dispensing and misleading marketing reflects a regulatory system that understands the gap between clinical intent and market reality.

Before considering any GLP-1 drug, consult an endocrinologist, internal medicine specialist, or cardiologist. Do not purchase semaglutide or any GLP-1 drug online without a valid prescription from a qualifying specialist. Do not begin treatment without a metabolic evaluation and a clear understanding of the long-term commitment the drug requires.


Action This Week

If you are considering a GLP-1 drug, the single right step is to book a consultation with an endocrinologist, internal medicine specialist, or cardiologist. Wellness clinics and general practitioners cannot legally prescribe this drug class in India. If you have already received GLP-1 from an unqualified prescriber or online source, stop and book a specialist review now. The baseline metabolic workup (fasting lipid profile, which is a blood test for cholesterol and triglycerides, and HbA1c, which is the three-month average blood sugar test) is part of that specialist visit.


Stay informed on prescription drug regulation and health policy in India

SwasthiQ covers DCGI regulatory updates, clinical drug evidence, and India-specific health policy for patients and clinic owners. Subscribe to our monthly newsletter: evidence-based, no wellness-industry hype.

Subscribe at swasthiq.com

Think Care · Think SwasthiQ


Related reading: The dangerous fat burner market: what's actually in those supplements? | Why Indian women are having heart attacks younger than ever | Important annual medical tests every adult in India should know